ANGPT2 and hepatocellular carcinoma: Concerning the utilization of circulating Ang-2 levels as a predictive or prognostic biomarker in advanced HCC, Kaseb et al. reported that elevated Ang-2 plasma levels were associated with poor prognosis in advanced HCC patients treated with a combination of the bevacizumab and the oral tyrosine kinase inhibitor erlotinib [76].